{
    "clinical_study": {
        "@rank": "164919", 
        "acronym": "FIM-BRO-2013", 
        "arm_group": [
            {
                "arm_group_label": "Pulmonary Rehabilitation (PRP)", 
                "arm_group_type": "Other", 
                "description": "Pulmonary Rehabilitation (PRP)"
            }, 
            {
                "arm_group_label": "Pulmonary Rehabilitation plus oral nutritional supplement", 
                "arm_group_type": "Other", 
                "description": "Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)"
            }
        ], 
        "brief_summary": {
            "textblock": "The effect of Pulmonary Rehabilitation in patients with bronchiectasis (BC) is not\n      sufficiently studied. The aim of this study is to assess the clinical and biological\n      response of  a Pulmonary Rehabilitation Program (PRP) for 12 weeks in BC  vs  PRP plus\n      hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate\n      (HMB).\n\n      Methods: single center randomized controlled trial,  parallel treatment design:\n      Participants will be randomized assigned either will receive (n=14) PRP for 60 minutes, two\n      supervised sessions per week in the hospital and one unsupervised session at home vs PRP\n      (n=14) plus ONS (one can per day).\n\n      Outcome assessments will be performed at baseline, 12 weeks and 24 weeks:\n\n      1.- effort capacity &#8211;cardiopulmonary exercise test-,  2.- body composition\n      (anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance, phase\n      angle), 3.- peripheral muscle strength (dynamometry and respiratory -PEM (maximum expiratory\n      pressure)and PIM (minimum expiratory pressure)-), 4.- spirometry, 5.-  respiratory symptoms\n      (bronchorrhea, dyspnoea, exacerbations),6.-  level of physical activity (IPAQ questionnaire\n      plus objective physical activity (WGT3X)), 7.- quality of life (QOL-B-Spain) ,\n      8.-psychological symptoms (HASD) and 9.- biological markers of inflammation (leptin,\n      adiponectin, interleukin-6, tumor necrosis factor-alpha, ultrasensitive C-reactive protein,\n      GPR55 (G protein-coupled receptor 55) RNAm (messenger ribonucleic acid)  expression in white\n      blood cells) and oxidation (total antioxidant capacity, superoxide dismutase activity,\n      8-iso-prostaglandin F2a, Thiobarbituric acid reactive substances)."
        }, 
        "brief_title": "Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis", 
        "condition": "Bronchiectasis", 
        "condition_browse": {
            "mesh_term": "Bronchiectasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients  ages from 18-80 (both included)\n\n          -  Patients with bronchiectasis, not cystic fibrosis bronchiectasis.\n\n          -  Bronchiectasis diagnosed by high resolution computed tomography (HRCT). of the chest\n\n          -  Patients followed in Bronchiectasis and Cystic Fibrosis Units in the Hospital.\n\n          -  BMI > 18.5 in patients under 65 years old, and > 20kg/m2 in patients over this age.\n\n          -  Ambulatory patients.\n\n        Exclusion Criteria:\n\n          -  Use of oral corticoids.\n\n          -  Respiratory exacerbation. If a patient had a respiratory exacerbation or a   recent\n             hospital admission, their participation will be postponed for at least 60 days til\n             any acute disease is resolved.\n\n          -  Prior oral or parenteral supplements intake.\n\n          -  Traumatological, neurological or cardiovascular diseases that prevent patients from\n             performing the training.\n\n          -  Life threatening hemoptysis in the past year.\n\n          -  Patients with cancer, major surgery in the previous three months, participating in\n             another study, patients who are pregnant or may become pregnant, patients with acute\n             intestinal disease, acute heart failure, severe hepatic failure or dialysis.\n\n          -  Gastrectomy, gastroparesis or other alterations of gastric emptying.\n\n          -  Enteral tube feeding, galactosemia, Fructosemia.\n\n          -  Allergy or known sensitivity to any ingredient of the enteral formula.\n\n          -  Cystic fibrosis.\n\n          -  Included in active list for transplantation.\n\n          -  Drug or alcohol abuse.\n\n          -  No informed consent signed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048397", 
            "org_study_id": "FIM-BRO-2013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pulmonary Rehabilitation (PRP)", 
                "intervention_name": "Pulmonary Rehabilitation", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Pulmonary Rehabilitation plus oral nutritional supplement", 
                "intervention_name": "Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Bronchiectasis.", 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "email": "gabrielm.olveira.sspa@juntadeandalucia.es", 
                "last_name": "GABRIEL OLVEIRA, MD, PhD", 
                "phone": "34951290305"
            }, 
            "facility": {
                "address": {
                    "city": "Malaga", 
                    "country": "Spain", 
                    "zip": "29009"
                }, 
                "name": "Gabriel Olveira"
            }, 
            "investigator": [
                {
                    "last_name": "GABRIEL OLVEIRA, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "CASILDA OLVEIRA, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "ROC\u00cdO MART\u00cdN-VALERO, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "ANTONIO DORADO, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "NURIA PORRAS, Grd", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "ANA GODOY, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "GEMMA ROJO, BD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "FRANCISCO JAVIER PALENQUE, Grd", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "ESPERANZA DO\u00d1A, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study of Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis: a Randomized Controlled Trial", 
        "other_outcome": [
            {
                "description": "Dynamometry", 
                "measure": "Peripheral muscle strength", 
                "safety_issue": "No", 
                "time_frame": "3rd and 6th month visits"
            }, 
            {
                "measure": "Change from baseline in respiratory symptoms (bronchorrhea, dyspnea, exacerbations) at 6 months.", 
                "safety_issue": "No", 
                "time_frame": "3rd and 6th month visits"
            }, 
            {
                "description": "IPAQ questionnaire plus objective physical activity", 
                "measure": "Level of physical activity", 
                "safety_issue": "No", 
                "time_frame": "3rd and 6th month visits"
            }, 
            {
                "description": "QOL-B-Spain", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "3rd and 6th month visits"
            }, 
            {
                "measure": "biological markers of  Biological markers of inflammation and oxidation", 
                "safety_issue": "No", 
                "time_frame": "3rd and 6th month visits"
            }
        ], 
        "overall_contact": {
            "email": "gabrielm.olveira.sspa@juntadeandalucia.es", 
            "last_name": "GABRIEL OLVEIRA, MD, PhD", 
            "phone": "34951290305"
        }, 
        "overall_contact_backup": {
            "email": "curra.linares@gmail.com", 
            "last_name": "FRANCISCA LINARES, MD", 
            "phone": "34951290305"
        }, 
        "overall_official": {
            "affiliation": "Andaluz Health Service", 
            "last_name": "GABRIEL OLVEIRA, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in oxygen uptake at peak exercise (VO2max) in cardiopulmonary exercise test (Before and after Rehabilitation-at 3 and 6 months)", 
            "safety_issue": "No", 
            "time_frame": "3rd and 6th month visits"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048397"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance.", 
            "measure": "Body composition", 
            "safety_issue": "No", 
            "time_frame": "3rd and 6th month visits"
        }, 
        "source": "Fundaci\u00f3n P\u00fablica Andaluza para la Investigaci\u00f3n de M\u00e1laga en Biomedicina y Salud", 
        "sponsors": {
            "collaborator": {
                "agency": "Fundaci\u00f3n P\u00fablica Andaluza Progreso y Salud", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n P\u00fablica Andaluza para la Investigaci\u00f3n de M\u00e1laga en Biomedicina y Salud", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}